Pfizer whistleblower lawsuits have driven more than $4 billion in criminal fines, civil penalties, and settlements since the early 2000s, making the company one of the most frequent False Claims Act defendants in the pharmaceutical industry. The cases, filed by former sales representatives, marketing executives, physicians, and a clinical trial auditor, have centered on off-label promotion of drugs including Neurontin, Bextra, Genotropin, Protonix, Rapamune, and Nurtec ODT, along with a still-pending suit tied to the company’s COVID-19 vaccine trial.
How These Cases Get Filed
The federal False Claims Act lets private citizens, called relators, sue on behalf of the government when a company defrauds programs like Medicare and Medicaid. These are known as qui tam actions. The whistleblower files under seal in federal court while the Department of Justice investigates, then decides whether to intervene or let the relator go it alone.
If the case recovers money, the whistleblower gets a share: 15% to 25% when the government intervenes, 25% to 30% when it does not. The statute also protects relators from retaliation, entitling them to reinstatement, double back pay, and other damages if they are fired or harassed for reporting.
Neurontin: The First Major Case (2004)
The pattern began with David Franklin, a former medical liaison at Warner-Lambert, which Pfizer acquired in June 2000. Franklin filed his suit in 1996, alleging the company promoted the epilepsy drug Neurontin for conditions it was never approved to treat, including bipolar disorder, pain disorders, migraines, and ADHD. Scientific studies had shown the drug was not effective for several of those uses.
The tactics Franklin described were aggressive. Warner-Lambert used employees like him to pose as independent scientific experts while promoting off-label uses, paid physicians to attend lavish “consultant meetings” that were really promotional events, funded supposedly independent medical education programs while controlling the content behind the scenes, and paid doctors to let sales representatives shadow them during patient visits.
In May 2004, Warner-Lambert pleaded guilty to two counts of misbranding, a felony given the company’s prior conviction history. The total resolution exceeded $430 million, including a $240 million criminal fine and $190 million in civil settlements covering federal Medicaid, state Medicaid, and consumer harm. Franklin received about $24.6 million. Pfizer entered its first Corporate Integrity Agreement with the HHS Office of Inspector General as part of the deal.
Bextra and the $2.3 Billion Settlement (2009)
Even under that first integrity agreement, Pfizer was building toward a larger reckoning. John Kopchinski, a West Point graduate and Gulf War veteran who had worked as a Pfizer sales representative in South Florida since 1992, filed a whistleblower suit in 2003. He alleged the company was illegally marketing the painkiller Bextra for uses and doses the FDA had never approved.
Bextra was approved only for rheumatoid arthritis, osteoarthritis, and menstrual pain. Kopchinski said he was told to distribute 20-milligram samples to orthopedists and rheumatologists even though that dose was approved only for menstrual pain, and he was never directed to call on gynecologists who would actually treat that condition. Sales representatives got a $50 bounty for each doctor they persuaded to put Bextra into surgical care protocols and were pushed to promote doses as high as eight times the approved starting amount. They were also told to claim Bextra was safer and more effective than Merck’s Vioxx, a claim the FDA had never approved.
Kopchinski explained his decision this way: “In the Army I was expected to protect people at all costs. At Pfizer I was expected to increase profits at all costs, even when sales meant endangering lives.” He cited Franklin’s Neurontin case as his inspiration.
His suit was the largest piece of what became a sprawling investigation. In September 2009, the Department of Justice announced a $2.3 billion settlement, then the largest healthcare fraud settlement in its history. It covered Bextra along with the antipsychotic Geodon, the antibiotic Zyvox, and the anti-epileptic drug Lyrica. Six separate whistleblower suits had been filed.
The settlement had two sides. Pfizer subsidiary Pharmacia & Upjohn pleaded guilty to a felony misbranding charge and paid a $1.195 billion fine plus $105 million in forfeiture. On the civil side, Pfizer paid $1 billion to resolve False Claims Act allegations, with about $669 million going to the federal government and $331 million to the states. The government alleged Pfizer had also paid kickbacks to doctors to prescribe and endorse Bextra off-label, exposing patients to risks of heart attack, stroke, and pulmonary embolism. Bextra had already been withdrawn from the market in April 2005.
Kopchinski received more than $51.5 million from the federal recovery, plus additional state shares. Pfizer entered a second Corporate Integrity Agreement running through 2014.
Genotropin: The Rost Case
Around the same time Kopchinski was filing, Dr. Peter Rost, a former Vice President of Marketing at Pharmacia, filed his own qui tam action in June 2003. Rost alleged Pharmacia illegally promoted Genotropin, a synthetic human growth hormone, for off-label uses including anti-aging and pediatric growth enhancement. He described sales bonuses tied to off-label prescriptions, a “study program” that funneled cash and luxury trips to prescribing doctors, discount pricing to anti-aging clinics and internet vendors, and paid consultants promoting unapproved uses.
The government declined to intervene after investigating for over two years, and the district court eventually granted summary judgment to Pfizer in September 2010, finding insufficient evidence linking the conduct to specific false claims. On a parallel track, the Department of Justice pursued its own criminal investigation, and Pfizer pleaded guilty to related charges in April 2007, paying $34.7 million.
Protonix: Two Settlements
Pfizer’s 2009 acquisition of Wyeth brought more whistleblower exposure. Wyeth had promoted the heartburn drug Protonix, approved in February 2000 only for short-term treatment of erosive esophagitis, a condition diagnosable only by endoscopy. The government alleged Wyeth trained its sales force to push Protonix for all forms of gastroesophageal reflux disease, including common symptomatic heartburn, and kept doing so after FDA warnings that the promotional materials were misleading.
Wyeth also promoted Protonix as the “best PPI for nighttime heartburn” without clinical support, and used what it called “branducation” internally, funding continuing medical education while secretly controlling topics, speakers, and content to drive off-label prescribing.
In December 2012, Pfizer paid $55 million plus interest to resolve the off-label promotion allegations covering conduct from February 2000 through June 2001. In 2016, it paid a far larger $784.6 million to resolve a separate set of Protonix allegations, this time over Wyeth’s failure to pay proper Medicaid rebates. The government charged that Wyeth had secretly offered bundled discounts on Protonix to thousands of hospitals without reporting those prices as the “best price” to Medicaid, causing hundreds of millions in overpayments. Two whistleblowers brought that case: Lauren Kieff, a former AstraZeneca sales representative, and Dr. William LaCorte, a New Orleans physician. They collectively received about $98 million.
Rapamune (2013)
Another Wyeth liability Pfizer inherited involved Rapamune, an immunosuppressive drug approved only for kidney transplant patients. Three former employees filed whistleblower suits alleging Wyeth trained sales staff to promote Rapamune for heart, liver, pancreas, and lung transplants, used bonuses to incentivize off-label sales, and paid speakers to promote the drug at physician meetings. Internal files from 2006 showed roughly 90% of Rapamune sales, about $200 million, came from unapproved uses.
In 2013, Wyeth pleaded guilty to one count of drug misbranding and paid $490.9 million to resolve criminal and civil liabilities. The civil piece included $257.4 million for false claims to Medicare, Medicaid, and TRICARE.
Brook Jackson and the COVID-19 Vaccine Trial
The most prominent recent case involves Brook Jackson, a clinical trial auditor with more than 15 years of experience who was hired in September 2020 as a regional director at Ventavia Research Group, a contract research organization running sites for Pfizer’s phase III COVID-19 vaccine trial.
Jackson documented what she described as widespread data integrity and safety failures at Ventavia’s sites. In a November 2021 investigative report in The BMJ, the problems included:
- Internal notes from August 2020 recording staff being “verbally counseled for changing data and not noting late entry.”
- Drug assignment printouts left in participant charts accessible to blinded personnel, with corrective action not taken until September 2020, after roughly 1,000 participants had enrolled.
- Participants left unmonitored after injections, vaccines not stored at proper temperatures, and mislabeled laboratory specimens.
- More than 100 outstanding queries from partner organization ICON older than three days, some involving severe symptoms and reactions.
- Inadequately trained vaccinators and insufficient staff to swab symptomatic participants for the trial’s primary endpoint.
Jackson emailed a formal complaint to the FDA on September 25, 2020. Ventavia fired her the same day, telling her she was “not a good fit.” The FDA acknowledged her report, and an inspector spoke with her, but she received no further updates. An FDA summary of trial inspections published in August 2021 showed none of Ventavia’s sites were among the nine inspected, with the agency saying data integrity verification was “limited” because the study was ongoing. Pfizer later hired Ventavia as a subcontractor for four additional clinical trials.
Jackson filed her qui tam suit in January 2021 in the Eastern District of Texas, captioned United States ex rel. Brook Jackson v. Ventavia Research Group, LLC; Pfizer, Inc.; Icon, PLC. In April 2023, the district court dismissed her substantive False Claims Act claims with prejudice, finding the alleged protocol violations did not meet the standard for a false claims suit. The federal government supported dismissal, saying it had known of the allegations for years and had authorized the vaccines anyway, and citing concerns about litigation burdens and conflicts with public health policy.
Jackson appealed to the Fifth Circuit, case number 24-40564. Oral argument was held on December 3, 2025, before Judges Elrod, Richman, and Willett. As of June 2026, no ruling had issued.
Nurtec ODT: The Biohaven Kickback Settlement (2025)
The most recent settlement involves conduct inherited through Pfizer’s October 2022 acquisition of Biohaven Pharmaceutical Holding Company. On January 24, 2025, Pfizer agreed to pay about $59.7 million to resolve allegations that Biohaven violated the Anti-Kickback Statute by paying improper remuneration to healthcare professionals to induce prescriptions of the migraine drug Nurtec ODT.
The Department of Justice alleged that between March 2020 and September 2022, Biohaven ran speaker programs lacking legitimate educational value, with prescribers attending repeat sessions and non-medical guests such as spouses and friends showing up at events held at high-end restaurants. The qui tam suit was filed by Patricia Frattasio, a former Biohaven sales representative, who received about $8.4 million. The settlement included the federal government, the Connecticut Attorney General’s office, 37 other states, and Puerto Rico. Pfizer had terminated the speaker programs after the acquisition, and the settlement included no admission of liability.
A Pattern of Repeated Violations
What sets Pfizer’s whistleblower history apart is the pattern rather than any single case. The company signed its first Corporate Integrity Agreement in 2004 after Neurontin. While still operating under that agreement, it engaged in the conduct that produced the record $2.3 billion Bextra settlement in 2009 and a second integrity agreement through 2014. Subsequent acquisitions layered on liabilities from Protonix, Rapamune, and Nurtec ODT. Total whistleblower-driven exposure for Pfizer and its subsidiaries now exceeds $4 billion since the early 2000s, with new cases still emerging as recently as 2025.